Tralokinumab Effectively Disrupts the IL-13/IL-13Rα1/IL-4Rα Signaling Complex but Not the IL-13/IL-13Rα2 Complex
Tralokinumab, a fully human mAb specifically targeting the IL-13 cytokine, has demonstrated clinical efficacy and safety in patients with moderate-to-severe atopic dermatitis. Tralokinumab binds IL-13 with high affinity, which prevents the interaction of IL-13 with IL-13Rα1 and subsequent signaling....
Saved in:
Main Authors: | Maxim A.X. Tollenaere (Author), Christina Mølck (Author), Ian Henderson (Author), Scott Pollack (Author), Philip Addis (Author), Helle Heibroch Petersen (Author), Hanne Norsgaard (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
IL-13Rα2 Status Predicts GB-13 (IL13.E13K-PE4E) Efficacy in High-Grade Glioma
by: Julian S. Rechberger, et al.
Published: (2022) -
Targeting interleukin-13 receptor α2 (IL-13Rα2) for glioblastoma therapy with surface functionalized nanocarriers
by: Ruijia Liang, et al.
Published: (2022) -
Expression of IL4Rα and IL13Rα1 are associated with poor prognosis of soft-tissue sarcoma of the extremities, superficial trunk, and retroperitoneum
by: Kyoung Min Kim, et al.
Published: (2021) -
IL-13Rα2 Is Involved in Resistance to Doxorubicin and Survival of Osteosarcoma Patients
by: Maryam Karamikheirabad, et al.
Published: (2024) -
Discovery and characterization of a monoclonal antibody targeting a conformational epitope of IL-6/IL-6Rα to inhibit IL-6/ IL-6Rα/gp130 hexameric signaling complex formation
by: Chun-Chi Chou, et al.
Published: (2022)